AstraZeneca PLC (AZN) stock
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was $13.74B, up 37.4% from the year before. Over ten years it grew 12.8% a year on average. The highest annual figure on record is $13.74B in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.74B | +37.4% |
| FY2024 | Dec 31, 2024 | $10.00B | +22.1% |
| FY2023 | Dec 31, 2023 | $8.19B | +118.1% |
| FY2022 | Dec 31, 2022 | $3.76B | +255.8% |
| FY2021 | Dec 31, 2021 | $1.06B | -79.5% |
| FY2020 | Dec 31, 2020 | $5.16B | +76.5% |
| FY2019 | Dec 31, 2019 | $2.92B | -13.7% |
| FY2018 | Dec 31, 2018 | $3.39B | -7.9% |
| FY2017 | Dec 31, 2017 | $3.68B | -25.0% |
| FY2016 | Dec 31, 2016 | $4.90B | +19.2% |
| FY2015 | Dec 31, 2015 | $4.11B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.16B | +487.0% |
| Q2 FY2025 | Jun 30, 2025 | $3.51B | +211.3% |
| Q2 FY2024 | Jun 30, 2024 | $2.75B | +113.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.46B | +398.2% |
| Q2 FY2022 | Jun 30, 2022 | $539.00M | -29.4% |
| Q2 FY2021 | Jun 30, 2021 | $1.13B | +21.8% |
| Q2 FY2020 | Jun 30, 2020 | $1.28B | – |
| Q2 FY2019 | Jun 30, 2019 | $493.00M | – |
| Q2 FY2018 | Jun 30, 2018 | $763.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $925.00M | – |
See a number that looks wrong?